BioCentury
ARTICLE | Clinical News

Fiasp regulatory update

November 17, 2016 2:33 PM UTC

EMA's CHMP recommended approval of Fiasp insulin aspart from Novo Nordisk to treat diabetes in adults. The company expects a decision from the European Commission in 1Q17. Fiasp is a faster-acting ins...

BCIQ Company Profiles

Novo Nordisk A/S

BCIQ Target Profiles

Insulin receptor (INSR)